// App-Quantinova.ai

e16542 : Retrospective study of treatment outcomes among metastatic castration-resistant prostate cancer patients receiving cabazitaxel and/or enzalutamide in later lines of therapy.

Researchers

Presenter

  • Bradford R Hirsch

Principal Investigators

  • Raymond Miao

  • Louis Hudspeth

  • Hong Wang

  • Debra Payne

  • John McCormick

Medical Centers

  • US Oncology Research, Dallas, TX

  • Sanofi, Bridgewater, NJ

  • McKesson Pharmaceutical Solutions, Toronto, ON, Canada

Locations

  • United States

  • Canada

Companies

  • McKesson Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Enzalutamide

  • Cabazitaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved